Advances in CAR‐Engineered Immune Cell Generation: Engineering Approaches and Sourcing Strategies

Abstract: Chimeric antigen receptor T‐cell (CAR‐T) therapy has emerged as a highly efficacious treatment modality for refractory and relapsed hematopoietic malignancies in recent years. Furthermore, CAR technologies for cancer immunotherapy have expanded from CAR‐T to CAR‐natural killer cell (CAR‐NK), CAR‐cytokine‐induced killer cell (CAR‐CIK), and CAR‐macrophage (CAR‐MΦ) therapy. Nevertheless, the high cost and complex manufacturing processes of ex vivo generation of autologous CAR products have hampered broader application. There is an urgent need to develop an efficient and economical paradigm shift for exploring new sourcing strategies and engineering approaches toward generating CAR‐engineered immune cells to benefit cancer patients. Currently, researchers are actively investigating various strategies to optimize the preparation and sourcing of these potent immunotherapeutic agents. In this work, the latest research progress is summarized. Perspectives on the future of CAR‐engineered immune cell manufacturing are provided, and the engineering approaches, and diverse sources used for their development are focused upon.

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
Online-Ressource
Language
Englisch

Bibliographic citation
Advances in CAR‐Engineered Immune Cell Generation: Engineering Approaches and Sourcing Strategies ; day:31 ; month:10 ; year:2023 ; extent:26
Advanced science ; (31.10.2023) (gesamt 26)

Creator
Chen, Zhaozhao
Hu, Yu
Mei, Heng

DOI
10.1002/advs.202303215
URN
urn:nbn:de:101:1-2023110114044409800745
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:49 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Associated

  • Chen, Zhaozhao
  • Hu, Yu
  • Mei, Heng

Other Objects (12)